A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Trial Profile

A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Pelareorep (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2016 Additional data of sub group analysis (female patients) published in Oncolytics Biotech media release.
    • 07 Jun 2016 Results analyzing efficacy and safety presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2016 Interim results from this trial will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Oncolytics Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top